These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 37493453)

  • 61. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
    Heitner R; Arndt S; Levin JB
    S Afr Med J; 2004 Aug; 94(8):647-51. PubMed ID: 15352589
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of switching from imiglucerase to velaglucerase alfa without dose reduction nor wash out in type 1 Gaucher disease.
    Serratrice C; Bengherbia M; Alessandrini M; Grosbois B; Camou F; Pers YM; Bismuth M; Marie I; Belmatoug N; Berger M;
    Blood Cells Mol Dis; 2014; 53(1-2):94-6. PubMed ID: 24411065
    [No Abstract]   [Full Text] [Related]  

  • 63. Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease.
    Hurvitz N; Dinur T; Becker-Cohen M; Cozma C; Hovakimyan M; Oppermann S; Demuth L; Rolfs A; Abramov A; Zimran A; Revel-Vilk S
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234327
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
    Giuffrida G; Lombardo R; Di Francesco E; Parrinello L; Di Raimondo F; Fiumara A
    J Med Case Rep; 2016 Nov; 10(1):315. PubMed ID: 27821156
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
    Wenstrup RJ; Kacena KA; Kaplan P; Pastores GM; Prakash-Cheng A; Zimran A; Hangartner TN
    J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Management, vaccination status and COVID-19 morbidity of patients with Gaucher disease in Germany during the COVID-19 pandemic.
    Niederau C; Regenbogen C; Fruehauf HM; Merkel M; Ziagaki A; Mengel E; Baerwald C; Muschol N; Staufner C; Lampe C; Gillessen A; Koehler JP; Vom Dahl S
    Z Gastroenterol; 2023 Apr; 61(4):375-380. PubMed ID: 37040780
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease.
    Elstein D; Cohn GM; Wang N; Djordjevic M; Brutaru C; Zimran A
    Blood Cells Mol Dis; 2011 Jan; 46(1):119-23. PubMed ID: 20727796
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study.
    Pena LDM; Barohn RJ; Byrne BJ; Desnuelle C; Goker-Alpan O; Ladha S; Laforêt P; Mengel KE; Pestronk A; Pouget J; Schoser B; Straub V; Trivedi J; Van Damme P; Vissing J; Young P; Kacena K; Shafi R; Thurberg BL; Culm-Merdek K; van der Ploeg AT;
    Neuromuscul Disord; 2019 Mar; 29(3):167-186. PubMed ID: 30770310
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Enzyme replacement therapy leading to improvement in myeloma indices in a patient with concomitant Gaucher disease.
    Harel R; Gavish I; Aviv A; Greenman Maravi N; Trougouboff P; Zimran A; Revel-Vilk S
    Intern Med J; 2022 May; 52(5):872-875. PubMed ID: 35538014
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Enzyme Replacement Therapy in a Patient with Gaucher Disease Type III: A Paradigmatic Case Showing Severe Adverse Reactions Started a Long Time After the Beginning of Treatment.
    Vairo F; Netto C; Dorneles A; Mittelstadt S; Wilke M; Doneda D; Michelin K; Ribeiro CB; Quevedo A; Vieira T; Nalin T; Lueska S; Schwartz IV
    JIMD Rep; 2013; 11():1-6. PubMed ID: 23430813
    [TBL] [Abstract][Full Text] [Related]  

  • 71. An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy.
    Goker-Alpan O; Longo N; McDonald M; Shankar SP; Schiffmann R; Chang P; Shen Y; Pano A
    Drug Des Devel Ther; 2016; 10():1771-81. PubMed ID: 27307708
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Recombinant macrophage targeted enzyme replacement therapy for Gaucher disease in India.
    Nagral A; Mewawalla P; Jagadeesh S; Kabra M; Phadke SR; Verma IC; Puri RD; Gupta N; Kishnani PS; Mistry PK
    Indian Pediatr; 2011 Oct; 48(10):779-84. PubMed ID: 22080680
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A novel mutation causing type 1 Gaucher disease found in a Japanese patient with gastric cancer: A case report.
    Hosoba S; Kito K; Teramoto Y; Adachi K; Nakanishi R; Asai A; Iwasa M; Nishimura R; Moritani S; Kawahara M; Minamiguchi H; Nanba E; Kushima R; Andoh A
    Medicine (Baltimore); 2018 Jul; 97(27):e11361. PubMed ID: 29979419
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Letter to the Editor on Pastores et al. Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease.
    Keutzer J; Gruskin D
    Blood Cells Mol Dis; 2017 May; 64():13-14. PubMed ID: 28301810
    [No Abstract]   [Full Text] [Related]  

  • 75. Treatment Efficiency in Gaucher Patients Can Reliably Be Monitored by Quantification of Lyso-Gb1 Concentrations in Dried Blood Spots.
    Cozma C; Cullufi P; Kramp G; Hovakimyan M; Velmishi V; Gjikopulli A; Tomori S; Fischer S; Oppermann S; Grittner U; Bauer P; Beetz C; Rolfs A
    Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32605119
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey.
    Schwartz IVD; Göker-Alpan Ö; Kishnani PS; Zimran A; Renault L; Panahloo Z; Deegan P;
    Mol Genet Metab Rep; 2018 Mar; 14():73-79. PubMed ID: 29326879
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Real-World Experiences with Taliglucerase Alfa Home Infusions for Patients with Gaucher Disease: A Global Cohort Study.
    Revel-Vilk S; Mansfield R; Feder-Krengel N; Machtiger-Azoulay N; Kuter D; Szer J; Rosenbaum H; Ferreira DC; Ruhrman-Shahar N; Wajnrajch M; Zimran A
    J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762854
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.
    Kishnani PS; DiRocco M; Kaplan P; Mehta A; Pastores GM; Smith SE; Puga AC; Lemay RM; Weinreb NJ
    Mol Genet Metab; 2009 Apr; 96(4):164-70. PubMed ID: 19195916
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial.
    Pleat R; Cox TM; Burrow TA; Giraldo P; Goker-Alpan O; Rosenbloom BE; Croal LR; Underhill LH; Gaemers SJ; Peterschmitt MJ
    Mol Genet Metab Rep; 2016 Dec; 9():25-28. PubMed ID: 27722092
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Direct and indirect effects of the SARS-CoV-2 pandemic on Gaucher Disease patients in Spain: Time to reconsider home-based therapies?
    Andrade-Campos M; Escuder-Azuara B; de Frutos LL; Serrano-Gonzalo I; Giraldo P; ; ;
    Blood Cells Mol Dis; 2020 Nov; 85():102478. PubMed ID: 32688219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.